Moderna (mrna.us) announced on Wednesday that its new coronal variant Omicron vaccine candidate booster needle showed better neutralizing antibody response to the new variant than its original coronal vaccine one month after inoculation. The enhanced dose of mrna-1273.214 also increased the level of neutralizing antibody against Omicron by nearly 8 times from baseline.
Access:
Moderna said that among 437 study participants, the enhancement needle of mrna-1273.214 was generally well tolerated, and its side effects were equivalent to those of mrna-1273.
The company plans to submit preliminary data to regulators in the next few weeks to prepare for the intensified vaccine candidate campaign in autumn.
Through its 2022q1 financial data, the biotechnology company based in Cambridge, Massachusetts reiterated its 2022 pre purchase agreement for covid-19 vaccine, which was about US $21billion.
